About this trial
Polymyalgia rheumatica (PMR) is the most common chronic inflammatory rheumatic disease among the elderly and is characterized by proximal extremity pain and fatigue. Treatment with prednisolone carries several significant adverse effects, and it is therefore essential to avoid unnecessary treatment. However, clinical diagnosis and even imaging such as positron emission tomography and computed tomography (PET/CT) has low diagnostic accuracy, which decrease after start of prednisolone. The purpose is to evaluate a new method to diagnose PMR with PET/CT using magnetic resonance imaging (MRI) for informing the interpretation of PET in 111 patients suspected of PMR at baseline and after 8 weeks prednisolone treatment. In addition, a treatment initiation strategy guided by clinical diagnosis combined with PET will be evaluated in 100 patients with newly diagnosed PMR.
Eligibility criteria
Qualifiers
Patients suspected of PMR seen at the Department of Rheumatology/internal medicine in Aarhus, Silkeborg, Horsens, Gødstrup, Randers, and Svendborg.
Age above 50.
Proximal extremity pain.
Disqualifiers
Oral, intravenous, intra-articular or intramuscular glucocorticoids within the last 2 months.
Previous prednisolone treatment for GCA/PMR.
Unable to give consent.
Proximal extremity pain duration for more than one year.
Trial design
Treatments tested in this trial
- PET/MRI
- PET/CT with 18-FDG
Treatment groups
Sponsors and collaborators
Kresten Krarup Keller
Lead sponsor
Aarhus University Hospital
Sponsor institution
Randers Regional Hospital
Collaborator
Central Jutland Regional Hospital
Collaborator
Gødstrup Hospital
Collaborator
Svendborg Hospital
Collaborator
Odense University Hospital
Collaborator
Regionshospitalet Horsens
Collaborator